Company PanGen Biotech Inc.

Equities

A222110

KR7222110009

Biotechnology & Medical Research

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Sales per Business

Sales per region

Sector Other Biotechnology & Medical Research

End-of-day quote Korea S.E. Other stock markets 23:00:00 16/05/2024 BST			5-day change	1st Jan Change
5,700 ^KRW	0.00%		-4.20%	-17.15%

03-27	PanGen Biotech Inc. announced that it has received KRW 3.999986631 billion in funding from CrystalGenomics Invites Co., LTD., Huons Co., Ltd., Hwail Pharmaceutical Co.,Ltd.	CI
03-18	PanGen Biotech Inc. announced that it expects to receive KRW 3.999986631 billion in funding from CrystalGenomics Invites Co., LTD., Huons Co., Ltd., Hwail Pharmaceutical Co.,Ltd.	CI

Pangen Biotech Inc. is a Korea-based company primarily engaged in the bio pharmaceuticals development technology transfer services. The Company mainly provides contract services for the manufacture of bio pharmaceuticals, bio pharmaceuticals development technology transfer services for the manufacture of Chinese hamster ovary (CHO) cell lines and the process of products and gains royalty from the services. The Company also provides reagents which are used for the development of bio pharmaceuticals. In addition the Company is also engaged in the development of bio pharmaceuticals such as Biosimilar EPO, Recombinant Factor VIII and Biosimilar G-CSF. The Company provides its services within domestic market and to overseas markets such as China, India, Mexico, America and Europe.

KRW in Million	2022	Weight	2023	Weight	Delta
EPO Medicine 46.6 %	3,796	58.4 %	3,410	46.6 %	-10.15%
Consignment Production (CMO) 21.8 %	1,049	16.1 %	1,593	21.8 %	+51.86%
Others 14.7 %	420	6.5 %	1,072	14.7 %	+155.31%
Technology Transfer (CDO) 13.2 %	547	8.4 %	969	13.2 %	+77.30%
Royalty 3.7 %	690	10.6 %	271	3.7 %	-60.76%

KRW in Million	2022	Weight	2023	Weight	Delta
South Korea 63.6 %	2,843	43.7 %	4,654	63.6 %	+63.71%
Overseas 36.4 %	3,658	56.3 %	2,661	36.4 %	-27.25%

Managers	Title	Age	Since
Jae-Seung Yoon CEO	Chief Executive Officer	63	28/01/10
Jae-Hong Jang DFI	Director of Finance/CFO	58	30/11/10
Jung-Soo Park CTO	Chief Tech/Sci/R&D Officer	54	28/01/10
Tae-Ho Byun COO	Chief Operating Officer	65	28/01/10

Members of the board	Title	Age	Since
Leonard Ariff bin Abdul Shatar BRD	Director/Board Member	60	-
Jae-Seung Yoon CEO	Chief Executive Officer	63	28/01/10
Jae-Hong Jang		58	-

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	11,414,683	7,274,889 ( 63.73 %)	0	63.73 %

Name	Equities	%	Valuation
CRYSTALGENOMICS INVITES CO., LTD. 16.68 %	1,903,405	16.68 %	9 M ₩
HUONS CO., LTD. 11.70 %	1,335,789	11.70 %	6 M ₩
HWAIL PHARMACEUTICAL CO.,LTD. 7.282 %	831,203	7.282 %	4 M ₩
DUOPHARMA BIOTECH 7.065 %	806,450	7.065 %	4 M ₩
Jae-Seung Yoon 3.504 %	400,000	3.504 %	2 M ₩
Na-yeon Kim 0.8761 %	100,000	0.8761 %	453 657 ₩
Jae-young Kim 0.8761 %	100,000	0.8761 %	453 657 ₩
Tae-Ho Byun 0.7500 %	85,606	0.7500 %	388 358 ₩
Sung-Tae Yoon 0.4474 %	51,072	0.4474 %	231 692 ₩
Jung-Soo Park 0.4312 %	49,220	0.4312 %	223 290 ₩

PanGen Biotech, Inc.

4F, Yeongtong Innoplex II 306 Sinwon-ro

16675, Suwon-si

http://www.pangen.com

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Other Biotechnology & Medical Research

	1st Jan change	Capi.
PANGEN BIOTECH INC.	-17.15%	48.3M
MODERNA, INC.	+33.63%	50.85B
IQVIA HOLDINGS INC.	-0.09%	42.82B
LONZA GROUP AG	+49.62%	42.03B
CELLTRION, INC.	-4.96%	29.55B
ICON PUBLIC LIMITED COMPANY	+11.18%	26.11B
ALNYLAM PHARMACEUTICALS, INC.	-21.95%	19.13B
BIO-TECHNE CORPORATION	+8.61%	13.05B
MEDPACE HOLDINGS, INC.	+28.31%	12.16B
UNITED THERAPEUTICS CORPORATION	+24.73%	12.08B

Other Biotechnology & Medical Research